Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Published on Friday, 08 June 2012 18:09 Written by TradersHuddle Staff
THE WOODLANDS, Texas, June 8, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.
Lexicon has completed dosing in a Phase 2b study of LX4211 in 299 patients with type 2 diabetes and expects to report top-line results at the end of June.
All posters will be available for download on Saturday morning from Lexicon's corporate website www.lexpharma.com.
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.
- Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
- Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
- Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
- Lexicon to Report First Quarter Financial Results on May 10, 2013
- Lexicon To Present At The Needham Healthcare Conference
- Lexicon To Present At The Cowen Healthcare Conference
- Lexicon To Present At The RBC Capital Markets Healthcare Conference
- Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
- Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013
Related Partner Headlines
- Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved - Benzinga
- Lexicon Prices 17.5M Shares At $2.25 per Share - Benzinga
- Lexicon Announces Proposed Common Stock Offering - Benzinga
- Lexicon Pharmaceuticals Announces Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome - Benzinga
- Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies - Benzinga
- Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results - Benzinga
- Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics - Benzinga
Recent Trading Ideas
Chesapeake Energy Is Close to Resistance
Windstream Is Near its 50 Day Moving Average
Applied Materials Is Close to Resistance
E*TRADE is Near a Key Support Area
First Solar is Near a Key Support Area
Trading Idea: Is Monster Worldwide close to Support?
Trading Idea: - Is Walgreen close to Resistance?
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,303.10 Trade time:4:36PM EDT Value change:▲8.60 (0.06%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,649.60 Trade time:4:35PM EDT Value change:▼0.91 (-0.06%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,459.14 Trade time:5:15PM EDT Value change:▼0.28 (-0.01%)
In The Wires
Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas
Global Wearable Technology Market - Worldwide Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2012 - 2018 Published By Marketresearchreports.biz
Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
Wyoming Has a New Top Home Alarm Company According to Trusted Independent Industry Resource - AlarmSystemReport.com
Latest Protect America Review Gets Updated by Top Home Alarm System Experts – AlarmSystemReport.com
Lucintel Forecasts Increased Demand from APAC and Middle East to Drive Global Military Aircraft Industry
Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment
Industrial And Commercial Hybrid & Pure Electric Vehicles Market Trends 2013 - 2023: Global Industry Analysis, Size, Share, Growth Drivers And Opportunities, Players